MEI Pharma (NASDAQ:MEIP) released its earnings results on Thursday. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.14), Bloomberg Earnings reports. MEI Pharma had a negative net margin of 1,651.87% and a negative return on equity of 60.75%.

MEIP stock opened at $4.49 on Friday. MEI Pharma has a 12-month low of $1.79 and a 12-month high of $5.14.

Several equities analysts recently issued reports on the stock. Cann restated a “buy” rating and issued a $7.50 target price on shares of MEI Pharma in a report on Friday. SunTrust Banks assumed coverage on shares of MEI Pharma in a report on Friday, July 13th. They issued a “buy” rating and a $12.00 target price on the stock. Zacks Investment Research lowered shares of MEI Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, July 18th. Stifel Nicolaus upgraded shares of MEI Pharma from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a report on Thursday, July 26th. Finally, Wells Fargo & Co upgraded shares of MEI Pharma from a “market perform” rating to an “outperform” rating in a report on Wednesday, June 6th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $7.58.

In other MEI Pharma news, COO David M. Urso sold 9,500 shares of MEI Pharma stock in a transaction on Tuesday, August 7th. The shares were sold at an average price of $3.58, for a total value of $34,010.00. Following the completion of the sale, the chief operating officer now directly owns 33,606 shares of the company’s stock, valued at $120,309.48. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 5.25% of the company’s stock.

About MEI Pharma

MEI Pharma, Inc, an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.

Recommended Story: Diversification For Individual Investors

Earnings History for MEI Pharma (NASDAQ:MEIP)

Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with's FREE daily email newsletter.